ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, today announced that its subsidiary, BioStrand, is
collaborating with PGxAI to leverage BioStrand's patented
Foundation AI Model, LENSai. This collaboration advances the
precision medicine field of pharmacogenomics and supports LENSai
Application Programming Interface (“API”) commercial rollout
through expanding LENSai features and market reach.
Pharmacogenomics, the study of how genetic variations affect
drug response, is integral to IPA’s goal to efficiently create
tailored therapies and improve patient outcomes. The vast amount of
genetic data has historically been difficult for researchers to
access, manage, and interpret. LENSai was built to address that
challenge through its unique ability to analyze Large Language
Models simultaneously with many disparate forms of research and
patient data. LENSai was recently made available by BioStrand to
certain current and prospective partners through an API.
BioStrand’s collaboration with PGxAI is an important next step
aimed at providing LENSai users the ability to apply
pharmacogenetic analysis, reflecting our shared mission of better
healthcare solutions through advanced technology.
“The work we’ve begun with PGxAI marks a significant application
of LENSai to a critical real-world challenge, enabling the
development of a unique pharmacogenomics AI model,” said Dr.
Jennifer Bath, President, and CEO of IPA. “With more genomic data
and new pharmacogenetic insights, more advanced methods are
urgently needed to analyze and predict treatment responses and
adverse drug reactions. We believe that LENSai offers a potentially
groundbreaking approach to creating an adaptive AI model that is
designed to predict individual patient responses to both existing
and new drugs.”
Mike Zack, MD, PhD, CEO of PGxAI, commented, “We are excited to
partner with BioStrand, a leader in AI-powered biotherapeutic
solutions. Our collaboration aims to create a transformative AI
model for the pharmacogenomics sector, enhancing our ability to
predict effective and safe therapies. This partnership represents a
significant step toward revolutionizing personalized medicine.”
Allan Gobbs, Executive Chairman of PGxAI, added, “The clinical
value of pharmacogenomics is increasingly recognized by healthcare
providers and payers. We believe that our model will enable
unprecedented personalization and precision in pharmacogenetic
recommendations, potentially transforming medication prescription
practices on a global scale.”
Despite advancements in generative AI, vector search, and
multi-omics, practical applications of precision medicine remain
limited, contributing to over 30% of adverse drug reactions, as
noted in The Lancet1. By sequencing the human genome and cataloging
genetic variants, we can better understand and predict how patients
will respond to specific drugs. Integrating pharmacogenomics with
Electronic Health Records (EHRs) and Artificial Intelligence (AI)
offers significant potential to personalize treatments and enhance
patient outcomes.
A robust AI model in this field has the potential to
revolutionize the $400 billion(2) prescription drug market,
significantly improving patient outcomes and driving innovation in
precision medicine. This presents a compelling investment
opportunity to transform healthcare by delivering cutting-edge
solutions in the rapidly evolving precision medicine landscape.
Dirk Van Hyfte, MD, PhD, Head of Technology at IPA and
Co-Founder of BioStrand, stated, “We are thrilled to deploy our
LENSai software, available through API, to support PGxAI’s
cutting-edge initiatives. Our collaboration is set to enhance
rational drug design by integrating advanced AI analysis of vast
genomic data, enabling the precise tailoring of therapies to
individual genetic profiles. This approach not only boosts the
efficacy and safety of treatments but also streamlines the drug
development process, reducing both timelines and costs. Our
technology is developed to help optimize drug therapies for
specific patient needs, marking a significant advancement in
personalized medicine.”
1
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01841-4/abstract
(2)
https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2023
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
About PGxAI
PGxAI is a leading AI-powered pharmacogenetics platform that is
transforming precision medicine through proprietary algorithms and
real-world data analysis. In partnership with InterSystems, PGxAI
utilizes advanced tools like vector search and generative AI to
analyze extensive real-world data, addressing challenges in drug
selection, dosage personalization, and identifying significant
drug-drug interactions. Contact email - admin@pgx.ai Corporate
presentation use this link
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
potential of LENSai and the collaboration with PGxAI, the impact
technologies, including their benefits, and statements relating to
IPA’s expected increased revenue streams and financial growth. In
respect of the forward-looking information contained herein, IPA
has provided such statements and information in reliance on certain
assumptions that management believed to be reasonable at the
time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results, risks
that the expected healthcare benefits including lowering
development timeliness, and costs and that development of targeted
treatments with higher efficacy and lower side effects will not be
achieved, risks that the benefits to drug discovery, protein-based
therapeutics, and synthetic biology won't be achieved, in addition
actual results could differ materially from those currently
anticipated due to a number of factors and risks, as discussed in
the Company’s Annual Information Form dated July 10, 2023 (which
may be viewed on the Company’s profile at www.sedar.com), and the
Company’s Form 40-F, dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking information contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625615288/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024